News updates

What's new in metastatic breast cancer research

http://www.slideshare.net/DanaFarber/mbc-2013-talk-3-whats-new-in-metastatic-research-and-clinical-trials-mg-edited

AIDS Drug may work against cancer:
http://www.reuters.com/article/2013/10/25/us-cancer-hiv-idUSBRE99O0R920131025

More Satisfied Patients Die Sooner?

http://www.forbes.com/sites/kaifalkenberg/2013/01/02/why-rating-your-doctor-is-bad-for-your-health/

Also by Forbes, super computer Watson working on matching patients to clinical trials at MD Anderson
http://www.forbes.com/sites/bruceupbin/2013/10/18/ibms-watson-now-tackles-clinical-trials-at-md-anderson-cancer-center/

Tiny Pacemaker

Massive innovation in computer/cell phone/battery technologies enables this tiny pacemaker.
http://www.bbc.co.uk/news/technology-24535624

Within a decade, it could be even smaller with better battery life.   Innovation never stops.  It never stopped before and will not stop in the future.   Without even knowing a lot what we know today about immune system, HIV got a cure within 15 years of the virus being first discovered.

Are we the cancer patients, including the breast cancer patients the only ones stuck in an innovation-deficient hell, where the word "cure" dare not appear in peer reviewed scientific journals?   There are lots of hope, lots of interesting research, but the focus on metastasis is not always there.  Hopefully this is changing:
http://wrbw.membercenter.worldnow.com/story/23667473/fifteen-leading-charities-and-advocacy-groups-join-forces-to-change-the-way-metastatic-breast-cancer-is-understood-and-to-increase-focus-on-research



http://www.ncbi.nlm.nih.gov/pubmed/22956040
http://www.eurekalert.org/pub_releases/2013-10/gcrc-dav101513.php

Valproic acid encourages virus to fight cancer.   Dandy


http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=3179

OMI helps identify therapy response easily.

BXQ-350 for pancreatic cancer and brain cancer

This is about BXQ-350 for pancreatic cancer and brain cancer:

http://news.cincinnati.com/apps/pbcs.dll/article?AID=/201310130522/NEWS10/310130052&nclick_check=1

Quote from:

Getting this far has been an achievement of its own for Bexion’s team. Fewer than 10 percent of drugs that undergo animal testing ever make it to phase 1 human trials.

And its challenges are just beginning. About 10 percent of drugs that get this far ultimately gain U.S. Food and Drug Administration approval, a total that drops to 4.7 percent for cancer drugs, according to a 2011 study.

Triple-negative tumors targetted with cystine transporter blocker

http://www.eurekalert.org/pub_releases/2013-10/uoc--tbc100213.php

Timmerman found that she could significantly slow growth of triple-negative tumors using an FDA-approved anti-inflammatory drug called sulfasalazine to block a specific cystine transporter called xCT. While sulfasalazine itself would not be appropriate for treating cancer, Timmerman said, it could serve as a "lead compound" that could be used to develop drugs that specifically target xCT on tumor cells.